Allium Medical

Executive Summary

Allium Medical is an Israeli med-tech company specializing in self-expanding, fully retrievable polymeric stents for urologic and biliary applications. Founded in 2008 and headquartered in Caesarea, the company employs 50–200 people and operates at a commercial stage with CE-marked products including ureteric, bulbar urethral, triangular prostatic, round posterior, and biliary stents. Its proprietary nitinol-based lattice architecture combines flexibility with radial strength, enabling stents to remain indwelling for up to three years while providing minimally invasive, curative solutions for strictures and obstructions. The platform is designed to improve patient quality of life by reducing the need for repeated interventions. Allium Medical holds a strong position in the European and select international markets, competing with metal and plastic stent alternatives. Its core differentiator—fully retrievable polymeric stents with long indwelling times—addresses a significant unmet need in urology (e.g., urethral strictures) and biliary tree obstructions. The company is poised for growth through geographic expansion, particularly into the US market via FDA clearance, and through development of next-generation stents with enhanced biocompatibility. Key upcoming catalysts include regulatory submissions, clinical study milestones, and potential strategic partnerships to accelerate market penetration. With a focused product portfolio and solid clinical evidence in existing markets, Allium Medical is well-positioned to capture share in the global stent market.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Ureteric Stent70% success
• Q4 2026Launch of Next-Generation Biliary Stent60% success
• Q1 2027Publication of Real-World Clinical Data on Urethral Stents80% success